Unicycive Therapeutics (UNCY) Corporate presentation summary

Corporate overview and strategy

• Focused on novel treatments for kidney disease, with a diversified portfolio and strong IP protection extending to 2031-2035.

• Lead asset OLC targets hyperphosphatemia in chronic kidney disease patients on dialysis; UNI-494 in development for acute kidney injury.

• Seasoned management team with proven track record in kidney drug development and commercialization.

• Cash runway extends into 2027, supported by $61.4 million in cash and $102 million in potential warrant funding.

Market opportunity and unmet need

• Hyperphosphatemia market exceeds $1 billion in the US, with over 550,000 dialysis patients and 80% receiving phosphate binders.

• 75% of patients fail to achieve target serum phosphorus levels despite six approved therapies, mainly due to high pill burden and poor adherence.

• Lower pill burden and improved palatability are the greatest unmet needs, as 62% of patients are non-adherent.

OLC product profile and clinical data

• OLC uses proprietary nanoparticle technology for high potency, low pill burden, and palatable formulation (swallowed whole, not chewed).

• Pivotal study showed 91% of patients achieved phosphate control, with 69% reaching targets at ≤1500 mg/day.

• Safety profile compares favorably to other phosphate binders, with most adverse events mild to moderate and low discontinuation rates.

• 79% of patients preferred OLC over prior therapy, citing ease of use and satisfaction.